Robust Cash Generation and EPS Growth
Operating cash flow of EUR 1.22bn (+EUR 189m YoY). Free cash flow before acquisitions EUR 770m (+15%), equaling 19% of sales. Diluted adjusted EPS EUR 1.49 (+16% YoY); EPS ex-PPA EUR 1.99 (+15%).
Successful Integration and M&A Contribution
Feed Enzyme Alliance acquisition (closed June 2025) contributed ~1% to sales and ~0.25–0.5 ppt to margin as expected; integration progressing and synergies realized ahead of plan (100% run rate of cost synergies a year early).
Innovation and R&D Strength
Launched 33 new biosolutions in 2025 (14 in Q4); ~25% of 2025 sales from products launched in last 5 years. R&D spend >EUR 400m, ~10,000 patents, 85% of 2025 launches IP-protected; AI adoption shortened lead discovery timelines from years to months.
Sustainability and ESG Progress
80% of sales aligned with at least one Sustainable Development Goal; achieved all six 2025 sustainability targets including 100% electricity from renewable sources.
Divisional Outperformance — Human Health & Food & Beverages
Human Health organic sales +10% (FY and Q4) driven by Dietary Supplements and Advanced Health & Nutrition. Food & Beverages organic sales +8% for year and +7% in Q4, driven by dairy, baking, meat and plant-based innovations (e.g., Galaya Smooth, Javora Enhance).
Improved Return Metrics and Capital Allocation
Adjusted return on invested capital (ex-goodwill) 10.1% (+>20% vs prior pro forma). Proposed total dividend payout DKK 6.5 per share (EUR 0.87 total), payout ratio 58.4% (within 40%–60% policy).
Solid Organic Sales Growth
Organic sales grew 7% for FY2025 (4% in Q4) despite exiting certain countries (~1ppt negative for the year). Reported sales grew 5% in EUR for the year.
Strong Profitability and Margin Expansion
Adjusted EBITDA margin of 37.1% for FY2025 (in line with guidance 37%–38%) — +100 bps vs prior year; adjusted gross margin at 59.1% (+240 bps YoY). Q4 adjusted EBITDA margin improved to 36.6% (+40 bps).